![Facts of HIV and AIDS transmission that will help you understand the nature of this endemic disease. | HHC Facts of HIV and AIDS transmission that will help you understand the nature of this endemic disease. | HHC](https://www.h-h-c.com/wp-content/uploads/2022/10/Transmission-of-HIV-1-1.jpg)
Facts of HIV and AIDS transmission that will help you understand the nature of this endemic disease. | HHC
![5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific 5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific](https://www.thelancet.com/cms/attachment/3c7aba1b-3db6-4ff9-ab99-2372235ed45f/gr1.jpg)
5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study - The Lancet Regional Health – Western Pacific
![Number of new HIV child infections vs. number of infections averted due to PMTCT, World, 1990 to 2022 Number of new HIV child infections vs. number of infections averted due to PMTCT, World, 1990 to 2022](https://ourworldindata.org/grapher/thumbnail/number-of-new-hiv-child-infections-vs-number-of-infections-averted-due-to-pmtct.png?imType=twitter)
Number of new HIV child infections vs. number of infections averted due to PMTCT, World, 1990 to 2022
![Two in One: HIV+COVID Screening and Testing Model | The George Washington University School of Medicine and Health Sciences Two in One: HIV+COVID Screening and Testing Model | The George Washington University School of Medicine and Health Sciences](https://cme.smhs.gwu.edu/sites/default/files/media/2022-10/TwoInOne_logo_clr_tag_linear.jpg)
Two in One: HIV+COVID Screening and Testing Model | The George Washington University School of Medicine and Health Sciences
![Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects Antiviral Activity, Safety and Pharmacokinetics of IDX899, a Novel HIV-1 NNRTI with High Barrier to Resistance, in Treatment-Naïve HIV-1-Infected Subjects](https://www.natap.org/2008/images/061208/Subjct-1.gif)